Icotrokinra vs Thymosin Alpha-1: Comparing Two Immunomodulatory Research Peptides
Icotrokinra, FDA-approved for psoriasis in 2026, blocks IL-23 receptors orally; Thymosin Alpha-1 rebalances T-cells in liver research. See how they compare.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Icotrokinra vs Thymosin Alpha-1 represent two structurally distinct approaches to immune-pathway research: one an FDA-approved oral peptide antagonist for a dermatologic autoimmune condition, the other an investigational immune-rebalancing peptide studied primarily in infectious and hepatic disease models. Researchers comparing the two are often trying to understand how modern peptide drug design addresses immune dysregulation from opposite directions — blocking a single pro-inflammatory receptor versus restoring broader T-cell homeostasis.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Icotrokinra is an FDA-approved oral macrocyclic peptide that blocks the IL-23 receptor and has demonstrated efficacy in Phase 3 psoriasis trials, while Thymosin Alpha-1 is an investigational immunomodulatory peptide studied for restoring T-cell balance in conditions like hepatitis B-related liver failure — the two occupy different regulatory tiers and different research niches within immunomodulatory peptide science.
TL;DR:
- Icotrokinra (JNJ-2113/ICOTYDE) is FDA-approved (March 2026) for moderate-to-severe plaque psoriasis; Thymosin Alpha-1 remains investigational in the jurisdictions reviewed here.
- Icotrokinra works by antagonizing the IL-23 receptor; Thymosin Alpha-1 works by rebalancing regulatory and effector T-cell populations and moderating cytokine output.
- Icotrokinra's strongest published evidence comes from the ICONIC Phase 3 psoriasis program; Thymosin Alpha-1's strongest recent evidence comes from a randomized controlled trial in HBV-related acute-on-chronic liver failure.
- Icotrokinra is not 503A compounding-eligible given its approved-drug status; Thymosin Alpha-1's compounding status differs by jurisdiction and formulation.
- The two peptides are rarely direct substitutes — research selection typically depends on whether the target pathway is IL-23/IL-17 driven inflammation or broader T-cell/cytokine dysregulation.
Icotrokinra: mechanism and evidence base
Icotrokinra, also known as JNJ-2113 or JNJ-77242113 and marketed as ICOTYDE, is a first-in-class oral macrocyclic peptide that antagonizes the interleukin-23 receptor (IL-23R). Because IL-23 signaling is a well-established driver of psoriatic inflammation, blocking the receptor selectively suppresses downstream production of IL-17A, IL-17F, IL-22, and TNF-α without disrupting IL-12 signaling, which shares a receptor subunit with IL-23 but serves distinct immune functions. The compound's macrocyclic structure — built from natural and noncanonical amino acids cyclized via a disulfide bond — is notable in peptide chemistry because it confers oral bioavailability, a property historically difficult to achieve with peptide therapeutics that are typically degraded by gastrointestinal proteases.
The primary published evidence comes from the ICONIC Phase 3 program, which enrolled roughly 2,500 patients across four randomized, double-blind, placebo-controlled studies (PMID 40278440, published 2026). In the pivotal ICONIC-LEAD trial (NCT06934226), 65% of patients achieved IGA 0/1 (clear or almost clear skin) and 50% achieved PASI 90 at week 16. Head-to-head data from the ICONIC-ADVANCE 1 and 2 studies reported superiority over deucravacitinib, an oral TYK2 inhibitor used as an active comparator. Icotrokinra also met its primary endpoint in a separate ulcerative colitis study, suggesting the IL-23R antagonism mechanism may extend beyond dermatologic applications into other IL-23-driven inflammatory conditions. Full compound data, including chemistry and regulatory details, is available on the Icotrokinra library profile.
Thymosin Alpha-1: mechanism and evidence base
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymosin fraction 5, studied for decades as an immune-modulating agent across infectious disease, oncology-adjacent, and vaccine-adjuvant research contexts. Rather than blocking a single receptor, Tα1's proposed mechanism involves dual regulation of T-cell subpopulations: suppressing excessive regulatory T-cell (Treg) expansion while preserving early effector T-cell (TE) activation. This dual action is mechanistically distinct from Icotrokinra's single-receptor-blockade approach — Tα1 is positioned as a homeostasis-restoring agent rather than a pathway inhibitor.
The most recent published evidence (PMID 41887933, DOI 10.2147/IDR.S34301, 2026) comes from a randomized controlled trial in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF, NCT03082885). In that trial, 73 patients received either standard medical therapy alone or standard therapy plus Tα1. Researchers found that 90-day transplant-free survivors exhibited higher baseline effector T-cell proportions and lower regulatory T-cell levels than non-survivors, and that Tα1 co-administration was associated with reduced Treg and CD226low/- Treg subset frequencies at weeks 4–8, along with a gradual decline in pro-inflammatory cytokines (IL-6, TNF-α, IFN-γ) without compromising early immune activation. The study's authors describe this as breaking the cycle of hyperinflammation and immune paralysis characteristic of ACLF progression. Additional compound data is available on the Thymosin Alpha-1 library profile.
Side-by-side comparison
| Property | Icotrokinra | Thymosin Alpha-1 |
|---|---|---|
| Structure | Oral macrocyclic peptide (disulfide-cyclized) | 28-amino-acid linear peptide |
| Primary mechanism | IL-23 receptor antagonism | Treg/TE cell rebalancing, cytokine moderation |
| Route studied | Oral | Injectable (subcutaneous, in cited trial context) |
| Lead indication studied | Moderate-to-severe plaque psoriasis | HBV-related acute-on-chronic liver failure |
| Key trial cited | NCT06934226 (ICONIC-LEAD) | NCT03082885 |
| Regulatory status | FDA Approved (March 18, 2026) | Investigational in the trial context reviewed here |
| 503A compounding eligibility | Not 503A eligible (approved-drug status) | Varies by formulation and jurisdiction |
| Broader research interest | Ulcerative colitis (Phase 2/3 signal) | Infectious disease, oncology-adjacent, vaccine adjuvancy |
Differential research applications
Researchers select between these two compounds based on which axis of immune dysregulation their model targets. Programs centered on IL-23/IL-17-driven skin or mucosal inflammation — psoriasis, and potentially inflammatory bowel disease given icotrokinra's ulcerative colitis signal — have published rationale for targeting the IL-23 receptor directly, since IL-23 sits upstream of the Th17 effector cascade implicated in those conditions. By contrast, research programs studying systemic immune collapse or hyperinflammation-to-immunoparalysis transitions, such as the HBV-ACLF trial cited above, have favored Tα1's broader T-cell rebalancing approach because the pathology in those models is not confined to a single cytokine axis.
Researchers cross-referencing evidence quality and trial status across compounds — including third immunomodulatory peptides such as KPV, which has been studied for melanocortin-receptor-mediated anti-inflammatory signaling — often use the site's evidence explorer tool to filter compounds by development stage and citation count before selecting a research direction.
Regulatory and compounding status
Icotrokinra received FDA approval on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older weighing at least 40 kg. As an FDA-approved drug product, it is not eligible for 503A bulk-substance compounding. WADA is expected to evaluate icotrokinra for prohibited-substance listing given its immunomodulatory mechanism, consistent with how other immune-pathway therapeutics have been treated on prior Prohibited Lists.
Thymosin Alpha-1's regulatory status varies considerably by jurisdiction and formulation; the HBV-ACLF trial cited here was conducted as a registered randomized controlled trial (NCT03082885) rather than under an approved-drug labeling framework in the markets reviewed. Researchers should consult current FDA guidance and the compound's individual library profile for jurisdiction-specific compounding and research-access details, since this status can change independent of the underlying research literature.
Cited studies
- PMID 40278440 — "Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents." (New England Journal of Medicine, 2026). DOI: https://doi.org/10.1056/NEJMoa2504187
- PMID 41887933 — "Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance." (Infection and Drug Resistance, 2026). DOI: https://doi.org/10.2147/IDR.S34301
Frequently asked questions
Q: Is icotrokinra the same as thymosin alpha-1?
A: No. They are structurally and mechanistically distinct peptides. Icotrokinra is a macrocyclic peptide that blocks the IL-23 receptor, while Thymosin Alpha-1 is a linear 28-amino-acid peptide that modulates T-cell subpopulations and cytokine output. They are not interchangeable in research protocols.
Q: Which peptide has stronger clinical trial evidence?
A: Both have randomized controlled trial support, but in different contexts. Icotrokinra's evidence base is larger, drawing on a roughly 2,500-patient Phase 3 program (ICONIC) that led to FDA approval, while Thymosin Alpha-1's most recent cited evidence comes from a smaller 73-patient randomized trial in a specific liver-failure population.
Q: Can icotrokinra be used for conditions other than psoriasis?
A: Published research indicates icotrokinra met its primary endpoint in a separate ulcerative colitis study, suggesting the IL-23R antagonism mechanism may have applications beyond dermatology. Further trials would be needed to establish this more broadly.
Q: Is thymosin alpha-1 available through 503A compounding pharmacies?
A: Compounding eligibility for Thymosin Alpha-1 varies by jurisdiction and current regulatory status, and can change independent of the research literature. Researchers should verify current status through the compound's library profile and applicable regulatory guidance rather than assuming continuous availability.
Q: Why would a researcher choose IL-23 receptor blockade over T-cell rebalancing?
A: The choice generally follows the underlying pathology being studied. IL-23 receptor blockade has published rationale for conditions where the Th17/IL-23 axis is a primary driver, such as psoriasis, whereas T-cell rebalancing approaches have been favored in research modeling broader immune dysregulation, such as the hyperinflammation-to-immunoparalysis transition seen in acute-on-chronic liver failure.
See also:
- Thymosin Alpha-1 vs LL-37: Immunomodulatory Research Profiles — another head-to-head comparison of immunomodulatory peptides with distinct mechanisms.
- Thymosin Alpha-1, Thymulin, and Thymalin: Thymic Peptide Family — places Thymosin Alpha-1 within its broader thymic peptide family.
- Best Peptides for Immune Function Research: 7 Compounds Ranked by Evidence — broader ranked overview of immunomodulatory research compounds.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.